In this post-hoc analysis of the EMPA-HEART CardioLink-6 trial, in contrast to the LV, SGLT2 inhibition with empagliflozin had no impact on RVMi in patients with T2DM, coronary artery disease and normal LVEF. This evidence concerns the gene SLC5A2 and coronary artery disorder.